Trial Profile

Orismilast for the treatment of moderate to severe ulcerative colitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orismilast (Primary)
Indications Ulcerative colitis
Focus Proof of concept; Therapeutic Use
Acronyms UCORIS

Most Recent Events

21 Feb 2025 According to an UNION therapeutics media release, company announced a poster presentation on new clinical data of oral orismilast in patients with UC at the 20th European Crohns and Colitis Organisation (ECCO) congress on February 19-22, 2025, in Berlin, Germany.
12 Feb 2024 New trial record
04 Jan 2024 According to an UNION therapeutics media release, The FDA has cleared UNIONs Investigational New Drug (IND) application for oral orismilast.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com